fiercebiotech.com

UniQure stock surges after FDA U-turn clears path to gene therapy filing

Standard

Read the original →

What this article backs

In its own words

FDA has pulled a U-turn on uniQure's Huntington's disease gene therapy, giving the biotech the OK to file for accelerated approval after previously demanding data from another trial.
fiercebiotech.com · Jun 17, 2026
giving the biotech the OK to file for accelerated approval after previously demanding data from another trial
fiercebiotech.com · Jun 17, 2026
FDA U-turn clears path to gene therapy filing
fiercebiotech.com · Jun 17, 2026

Corroborated by